Adamas Pharmaceuticals Inc (NASDAQ:ADMS): Sahm Adrangi’s Kerrisdale Capital filed an amended 13D.
You can check out Kerrisdale Capital’s latest holdings and filings here.
Please follow Kerrisdale Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Kerrisdale Capital or update its stock holdings.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Kerrisdale Partners Master Fund Ltd||1,473,247||0||1,473,247||0||1,473,247||6.5%|
Page 1 of 7 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
October 24, 2017
(Date of Event Which Requires Filing of this Statement)
appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)